ArticleBMC genomics2015
Genome mining for natural product biosynthetic gene clusters in the Subsection V cyanobacteria.
Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 67 citations in OpenAlex.
- Biosynthetic origin of anticancer dolastatin 15 reveals a noncanonical NRPS architecture enabling 2-keto acid activation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A guide to Direct Pathway Cloning (DiPaC) for natural product discovery.Essays in biochemistry · 2026Review
- Next-Generation Cyanobacterial Biocontrol Agents for Crop Fungal Diseases: Molecular Mechanisms, Omics Insights, Applications, and Biosafety Considerations.Journal of basic microbiology · 2026Review
- Multichassis Expression of Cyanobacterial and Other Bacterial Biosynthetic Gene Clusters.ACS synthetic biology · 2025Article
- Efficient Production of Shinorine and Mycosporine-Glycine-Alanine inJournal of agricultural and food chemistry · 2025Article
- Tandem ketone reduction in pepstatin biosynthesis reveals an FNature communications · 2025Article
- Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated CyanobacteriumJournal of natural products · 2025Article
- Genetic and biochemical diversity of terpene biosynthesis in cyanobacterial strains from tropical soda lakes.Frontiers in microbiology · 2025Article
- Genome assembly, characterization, and mining of biosynthetic gene clusters (BGCs) fromFrontiers in genetics · 2024Article
- Unique Initiation and Termination Mechanisms Involved in the Biosynthesis of a Hybrid Polyketide-Nonribosomal Peptide Lyngbyapeptin B Produced by the Marine CyanobacteriumACS chemical biology · 2023Article
- Biosynthesis of Lyngbyastatins 1 and 3, Cytotoxic Depsipeptides from anJournal of natural products · 2023Article
- Four new suomilides isolated from the cyanobacteriumFrontiers in microbiology · 2023Article
- In vivo and in silico screening for antimicrobial compounds from cyanobacteria.MicrobiologyOpen · 2022Review
- Natural Product Gene Clusters in the FilamentousLife (Basel, Switzerland) · 2021Article
- Article
- Mining of Cyanobacterial Genomes Indicates Natural Product Biosynthetic Gene Clusters Located in Conjugative Plasmids.Frontiers in microbiology · 2021Article
- Actinobacteria From Desert: Diversity and Biotechnological Applications.Frontiers in microbiology · 2021Review
- Cyanobacteria and Eukaryotic Microalgae as Emerging Sources of Antibacterial Peptides.Molecules (Basel, Switzerland) · 2020Review
- Article
- Genome Mining as New Challenge in Natural Products Discovery.Marine drugs · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyanobacteria are well known for the production of a range of secondary metabolites. Whilst recent genome sequencing projects has led to an increase in the number of publically available cyanobacterial genomes, the secondary metabolite potential of many of these organisms remains elusive. Our study focused on the 11 publically available Subsection V cyanobacterial genomes, together with the draft genomes of Westiella intricata UH strain HT-29-1 and Hapalosiphon welwitschii UH strain IC-52-3, for their genetic potential to produce secondary metabolites. The Subsection V cyanobacterial genomes analysed in this study are reported to produce a diverse range of natural products, including the hapalindole-family of compounds, microcystin, hapalosin, mycosporine-like amino acids and hydrocarbons.
resultsA putative gene cluster for the cyclic depsipeptide hapalosin, known to reverse P-glycoprotein multiple drug resistance, was identified within three Subsection V cyanobacterial genomes, including the producing cyanobacterium H. welwitschii UH strain IC-52-3. A number of orphan NRPS/PKS gene clusters and ribosomally-synthesised and post translationally-modified peptide gene clusters (including cyanobactin, microviridin and bacteriocin gene clusters) were identified. Furthermore, gene clusters encoding the biosynthesis of mycosporine-like amino acids, scytonemin, hydrocarbons and terpenes were also identified and compared.
conclusionsGenome mining has revealed the diversity, abundance and complex nature of the secondary metabolite potential of the Subsection V cyanobacteria. This bioinformatic study has identified novel biosynthetic enzymes which have not been associated with gene clusters of known classes of natural products, suggesting that these cyanobacteria potentially produce structurally novel secondary metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.